Table 2.
Characteristics of patients in the training set
| Sample ID | Age (years) | Sex | Bacterial isolation | Antibiotherapy before blood collection | Underlying diseases | Survival |
|---|---|---|---|---|---|---|
| Other sepsis (n = 13) | ||||||
| I001* | 52 | Male | Streptococcus non-group A or B | Ceftriaxone | - | Non-survivor |
| I002†‡ | 52 | Female | A. baumannii | Ceftazidime, bactrim | T2D, CRF, lung edema | Survivor |
| I004* ‡ | 45 | Male | Salmonella serotype B | Cloxacillin, ceftriaxone | T2D, arthritis | Survivor |
| I006* § | 37 | Male | C. albicans | Ceftriaxone, sulperazone, bactrim | HIV infection, tuberculosis | Survivor |
| I007* | 73 | Female | Corynebacterium spp. | - | NSAID-induced GI bleeding | Non-survivor |
| I008†¶ | 70 | Female | E. coli | Bactrim, ceftazidime | T2D | Survivor |
| I009* | 52 | Female | S. aureus | Ceftazidime, cloxacillin | T2D, knee abscess | Survivor |
| I010†‡¥ | 72 | Female | E. coli | Ceftriaxone | T2D, CRF | Survivor |
| I011* ¶ | 38 | Female | E. coli | - | HCV infection | Survivor |
| I012* § | 69 | Female | C. albicans | Ceftazidime | RF | Survivor |
| I013* | 74 | Female | Corynebacterium spp. | Ceftazidime, clarithromycin | Chronic heart failure, COPD | Survivor |
| I014* | 54 | Female | Salmonella spp. | Ceftriaxone, ceftazidime, levofloxacin | T2D, endometrial cancer, ITP | Survivor |
| I015* § | 41 | Male | C. albicans | Ceftazidime | HIV infection | Survivor |
| Septicemic melioidosis (n = 11) | ||||||
| M001* | 68 | Male | B. pseudomallei | Ceftazidime, bactrim | Chronic heart failure, COPD | Non-survivor |
| M002* | 43 | Female | B. pseudomallei | Ceftriaxone, ceftazidime | T2D | Survivor |
| M003* | 55 | Male | B. pseudomallei | Ceftazidime | - | Non-survivor |
| M006* | 46 | Male | B. pseudomallei | Ceftriaxone | T2D, chirrosis | Non-survivor |
| M007* | 50 | Male | B. pseudomallei | Ceftazidime, tazocin | Lung cancer | Survivor |
| M008* | 70 | Female | B. pseudomallei | Ceftazidime, bactrim | T2D | Non-survivor |
| M009* | 48 | Female | B. pseudomallei | Sulperazone | T2D | Survivor |
| M010* | 48 | Male | B. pseudomallei | Ceftriaxone, ceftazidime, doxycycline | T2D | Survivor |
| M012* | 56 | Male | B. pseudomallei | Sulperazone, bactrim, cetazidime | T1D, ARF | Survivor |
| M014* | 65 | Female | B. pseudomallei | Cloxacilin, ceftazidime | T2D, chirrosis | Non-survivor |
| M015* | 41 | Male | B. pseudomallei | Bactrim, ceftazidime | - | Survivor |
*Community-acquired septicemia; †hospital-acquired septicemia;‡mechanical ventilation;§taken immunosuppressive;¶urinary catheterized drugs; ¥blood transfused. ARF, acute renal failure; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; GI, gastrointestinal tract; NSAID, non-steroidal anti-inflammatory drug; RF, renal failure; T2D, type 2 diabetes; TP, idiopathic thrombocytopenic purpura.